CDKN2A and neoplasm: In the case of GBMs, metabolomics allowed for a better understanding of tumour progression and helped discover previously unknown roles of key cancer drivers, such as CDKN2A’s role in PUFA partitioning, while in TNBCs, it was shown that it can be used to better predict survival in patients, such as the BLIS transcriptomic subtype.